# US 2021/0078055 A1 · Method of preventing lamellar silica formation in glass container

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0078055 A1
- Document ID: US20210078055A1
- Status: Published application
- Kind: A1
- Application number: 16/959,663
- Filed: 2019-01-03
- Published: 2021-03-18
- Earliest claimed: 2018-01-03
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Yasser Nashed-Samuel; Jeremy Gastwirt
- Web page: https://patentgrep.com/patent/US20210078055A1

## CPC

- B08B 9/093: by the force of jets or sprays ({B08B9/0813} , B08B9/20 take precedence)
- A61J 1/06: Ampoules or carpules (syringe ampoules or carpules A61M5/28)
- A61J 1/065: {Rigid ampoules, e.g. glass ampoules}
- A61J 1/1468: {Containers characterised by specific material properties}
- B08B 17/02: Preventing deposition of fouling or of dust
- C03C 23/007: {by thermal treatment}
- C03C 23/0075: {Cleaning of glass (specially adapted to plate glass B08B11/00)}
- C03C 23/0085: {Drying; Dehydroxylation}
- C11D 7/08: Acids
- C11D 7/265: {Carboxylic acids or salts thereof}
- G01N 21/9027: {in containers after filling}
- G01N 23/2251: using incident electron beams, e.g. scanning electron microscopy [SEM]
- G01N 33/386: {Glass}
- C11D 2111/18: Glass; Plastics
- G01N 2223/652: impurities, foreign matter, trace amounts
- B08B: CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- C03C: CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C11D: DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods of preventing the formation of lamellar silica formation in a borosilicate glass container storing a pharmaceutical formulation in an interior of the glass container in accordance with embodiments of the disclosure can include washing the container and drying the container under extended dry conditions of at least 3000 ms.

## Claims

### Claim 1

A method for preventing lamellar silica formation in a borosilicate glass container storing a pharmaceutical formulation in an interior of the glass container, comprising:
prior to filling the glass container with the pharmaceutical formulation, washing the interior of the glass container with a pressurized water jet; and
drying the glass container by blowing compressed air into the interior of the glass container for at least 3000 ms wherein the glass container is washed and dried using a batch washer.

### Claim 2

A method for preventing lamellar silica formation in a borosilicate glass container storing a pharmaceutical formulation in an interior of the glass container, comprising:
prior to filling the glass container with the pharmaceutical formulation, washing the glass container with a pressurized water jet under conditions sufficient to remove contaminants,
drying the washed glass container; and
depyrogenizing the glass container by heating the dried glass container in an oven at a temperature of at least about 250° C., wherein the glass container remains stationary in the oven during heating.

### Claim 3

A method of preventing lamellar silica formation in a borosilicate glass container containing a pharmaceutical formulation in an interior of the glass container, comprising:
prior to filling the glass container with the pharmaceutical formulation, washing the glass container with a pressurized water jet under conditions sufficient to remove contaminants,
drying the washed glass container by blowing compressed air into the interior of the glass container for at least 3000 ms,
placing the dried glass container in a heat-safe container and covering the heat-safe container containing the dried glass container with a lid;
depyrogenizing the dried glass container contained in the covered heat-safe container.

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The method of claim 2, wherein the depyrogenation temperature is between 330° C. and 350° C.

### Claim 6

(canceled)

### Claim 7 (depends on 2)

The method of claim 2, wherein the dried glass container is held at a constant temperature of about 90° C. for about 60 minutes prior to depyrogenation.

### Claim 8 (depends on 2)

The method of claim 2, comprising drying the glass container using at least 3 drying cycles, each drying cycle comprising blowing compressed air into the interior of the glass container for at least 3000 MS.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 2)

The method of claim 2, wherein the glass container is washed by exposing the interior of the container to the pressurized water jet for a duration greater than 1000 ms.

### Claim 12

(canceled)

### Claim 13 (depends on 2)

The method of claim 2, wherein the pressurized water jet has a temperature of at least 72° C.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The method of claim 2, further comprising filling the glass container with the pharmaceutical formulation, wherein the pharmaceutical formulation comprises an acid selected from the group comprising citric acid, phosphoric acid, acetic acid, or salts thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the pharmaceutical formulation further comprises a polyol.

### Claim at position 18

-32. (canceled)

### Claim 33 (depends on 16)

The method of claim 16, wherein the pharmaceutical formulation further comprises an anionic surfactant.

### Claim 34 (depends on 16)

The method of claim 16, wherein the pharmaceutical formulation has a pH of 6 to 8.

### Claim 35 (depends on 2)

The method of claim 2, wherein filled glass container remains free of lamellar silica after storage of a pharmaceutical formulation comprising citric acid and polysorbate 80 within the glass container for at least 30 days at 40° C.

### Claim 36 (depends on 2)

The method of claim 2, wherein the glass container has a volume of 10 cc, and the glass container is washed by exposing the interior of the glass container to a pressurized water jet for at least 3000 ms.

### Claim 37 (depends on 2)

The method of claim 2, wherein the glass container has a volume of 50 cc and the glass container is washed by exposing the interior of the glass container to a pressurized water jet for at least 3000 ms.

### Claim 38 (depends on 2)

The method of claim 2, wherein the pressurized water jet has a pressure of at least 7.25 psi.

### Claim 39

A method of screening a glass container storing a pharmaceutical formulation for susceptibility to lamellar silica formation when filled with a pharmaceutical formulation, comprising:
filling a washed and depyrogenized glass container with a buffer for the pharmaceutical formulation, wherein the glass container comprises ions selected from the group comprising sodium, calcium, hydroxide, silicate, and combinations thereof;
storing the filled glass containers at a temperature of 40° C. for at least 14 days;
optically analyzing the buffer after storage for formation of one or more particles in the buffer;
when particle formation is observed, isolating the one or more particles from the buffer for structural and elemental analysis;
analyzing the isolated one or more particles using one or more of optical microscopy, scanning electron microscopy/energy dispersive X-ray spectroscopy (SEM/EDS), Fourier-transform infrared spectroscopy (FTIR), x-ray photoelectron spectroscopy (XPS), differential interference contrast microscopy (DIC), microflow imaging (MFI), and combinations thereof to determine a morphology of the particles and chemical composition; and
analyzing an interior surface of the glass container, once emptied and after isolating the one or more particles, for delamination-type deformation of the interior surface, wherein the presence of particles having a chemical composition comprising silicon, oxygen, and carbon, and the absence of delamination-type deformation of the interior surface of the glass container indicates susceptible to lamellar silica formation.

### Claim 40 (depends on 39)

The method of claim 39, wherein the glass container is a borosilicate glass container.

### Claim 41 (depends on 39)

The method of claim 39, wherein the buffer comprises one or more of citric acid, phosphoric acid, acetic acid, succinic acid, gluconic acid, histidine, polysorbate 80, polysorbate 20, hyaluronic acid, pluronic acid, sodium alginate, gelatin, chitosan, lecithin, mannitol, sucrose, sulfobutylether beta cyclodextrin, sodium chloride, and combinations thereof.

### Claim 42 (depends on 39)

The method of claim 39, further comprising spiking the buffer with between 5 and 10 ppm elemental silicon.
